PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that shareholders approved all proposals put forward by the Board of Directors at the Company's fifth annual General Meeting with a large majority. The meeting took place at the Chollerhalle in Zug, with 26,780,855 shares represented, corresponding to 80.85% of issued registered shares.
All six members of the Board of Directors proposed for re-election were appointed for a term ending at the conclusion of the next annual General Meeting 2027. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for a term ending at the conclusion of the next annual General Meeting 2027.
Other approved proposals included the re-election of the Statutory Auditors and the Independent Proxy, as well as the approval of the maximum aggregate amount of compensation of the Board of Directors and Executive Committee. Shareholders also granted discharge to all members of the Board of Directors and Executive Committee in office in the financial year 2025 for their activities. The Management Report, Statutory Financial Statements, Consolidated Financial Statements, and the report on non-financial matters for the financial year 2025 were approved, along with the Remuneration Report 2025 in a separate consultative vote.
The strong shareholder turnout and unanimous approval of all proposals indicate continued confidence in PolyPeptide's strategic direction and governance. As a specialized CDMO for peptide-based APIs, the company serves a fast-growing market with significant exposure to metabolic diseases, including GLP-1 therapies. The approval of financial statements and compensation packages ensures stability in leadership and operations.
The minutes of the AGM 2026 will be available within 15 days on the Company's website. The next annual General Meeting 2027 will be held on 7 April 2027. For more information, visit polypeptide.com or follow PolyPeptide on LinkedIn.
